A lower dosage of liraglutide is accepted for the treating type 2 diabetes and is sold under the brand Victoza. This is the first research specifically designed to investigate the efficacy of liraglutide for weight reduction in patients with type 2 diabetes at a dose of 3 mg, rather than surprisingly was found to work and tolerated for weight loss, said Zonszein, who was not mixed up in trial. We need these studies, as clinicians have a big issue trying to use higher doses of liraglutide in obese patients who have diabetes. Hopefully, the FDA shall change the arbitrary restrictions, he added.Abbott can be confirming its full-calendar year 2014 ongoing earnings-per-share assistance of $2.16 to $2.26, representing double-digit development at the mid-stage of the assistance range. Abbott continues to forecast net specified products for the entire year 2014 of $1.03 per share. Specified products include intangible amortization expenditure, charges associated with cost decrease initiatives, along with tax expense associated with a one-time repatriation of 2014 ex-U.S. Revenue, partially offset by a good adjustment to tax expenditure related to the resolution of varied tax positions from previous years.